Novartis raises 2026 core operating income outlook to flat to low-single-digit growth
NVS•Novartis raised its 2026 core operating income outlook to flat to low-single-digit growth at constant currencies, from a low-single-digit decline. Third-quarter core operating income rose 10% to $6.04 billion, while sales increased 4% to $14.52 billion.
1. Outlook raised
Novartis raised its 2026 core operating income outlook to flat to low-single-digit growth at constant currencies, from a low-single-digit decline, while keeping its forecast for low-single-digit net sales growth. Third-quarter core operating income rose 10% at constant currencies to $6.04 billion, and sales increased 4% to $14.52 billion, driven by priority brands and launches.
2. Long-term targets
The group reaffirmed its forecast for 5%-6% sales CAGR from 2025 to 2030 and mid-single-digit long-term growth, both at constant currencies. Its third-quarter core margin was 41.6%.
